-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The tumor suppressor protein p53 is mutated in more than half of human cancers
However, there is still much to be understood about the various mutations that cause the "loss of function" of proteins and other mutations that lead to the "gain of function" presumed to be malignant, such as the acceleration of cancer growth and spread (metastasis)
Some studies have observed a positive correlation between p53 mutations and aneuploidy.
Now, researchers at Vanderbilt University Medical Center have discovered that in cells expressing mutant p53, aneuploidy drives the function to acquire a phenotype
"The concept of mutant p53 gaining function was introduced more than 30 years ago.
Pietenpol is the Benjamin F.
In the current study, the researchers used CRISPR-Cas9 gene editing technology to develop two genetically identical epithelial cell line models containing p53 mutations
They found that the gain-of-function phenotype in vitro was only in cell lines that showed increased aneuploidy
Therefore, the researchers concluded that addressing the functional gain of mutant p53 must take into account the effects of chromosomal changes